Overview
Familial hypoaldosteronism is a rare inherited disorder of adrenal steroid biosynthesis characterized by deficient production of aldosterone, the principal mineralocorticoid hormone responsible for regulating sodium and potassium balance in the body. The condition primarily affects the renin-angiotensin-aldosterone system and can be caused by defects in different enzymatic steps of aldosterone synthesis. Two main forms are recognized: type I, caused by mutations in the CYP11B2 gene (encoding aldosterone synthase, also known as corticosterone methyl oxidase), which can be further subdivided into corticosterone methyl oxidase type I (CMO I) and type II (CMO II) deficiencies; and other rarer forms. The disorder predominantly affects the kidneys' ability to retain sodium and excrete potassium, leading to electrolyte imbalances. Clinical features typically present in infancy or early childhood and include failure to thrive, dehydration, salt-wasting episodes, hyponatremia (low blood sodium), hyperkalemia (high blood potassium), and metabolic acidosis. In severe cases, particularly in neonates and infants, life-threatening salt-wasting crises with vomiting, poor feeding, and cardiovascular collapse may occur. Interestingly, the clinical severity often improves with age, and many affected adults may be relatively asymptomatic or only mildly affected, likely due to compensatory mechanisms for sodium retention that mature over time. Treatment focuses on correcting the mineralocorticoid deficiency and electrolyte imbalances. In infancy and early childhood, management typically includes sodium chloride supplementation and, in some cases, fludrocortisone (a synthetic mineralocorticoid). As patients grow older, the need for treatment often decreases, and some adults may not require ongoing therapy. Regular monitoring of serum electrolytes and growth parameters is important, particularly during childhood. Genetic counseling is recommended for affected families.
Clinical phenotype terms— hover any for plain English:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Familial hypoaldosteronism.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Familial hypoaldosteronism at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Familial hypoaldosteronism.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Familial hypoaldosteronism.
Community
No community posts yet. Be the first to share your experience with Familial hypoaldosteronism.
Start the conversation →Latest news about Familial hypoaldosteronism
No recent news articles for Familial hypoaldosteronism.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Familial hypoaldosteronism
What is Familial hypoaldosteronism?
Familial hypoaldosteronism is a rare inherited disorder of adrenal steroid biosynthesis characterized by deficient production of aldosterone, the principal mineralocorticoid hormone responsible for regulating sodium and potassium balance in the body. The condition primarily affects the renin-angiotensin-aldosterone system and can be caused by defects in different enzymatic steps of aldosterone synthesis. Two main forms are recognized: type I, caused by mutations in the CYP11B2 gene (encoding aldosterone synthase, also known as corticosterone methyl oxidase), which can be further subdivided int
How is Familial hypoaldosteronism inherited?
Familial hypoaldosteronism follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Familial hypoaldosteronism typically begin?
Typical onset of Familial hypoaldosteronism is neonatal. Age of onset can vary across affected individuals.